MAPK8 and idiopathic pulmonary fibrosis: Another JNK inhibitor, CC-930, exhibits specificity for JNK1 and is currently in phase II clinical trials for idiopathic pulmonary fibrosis, but it presents some cardiac adverse effects (Krenitsky et al., 2012).